UCB, a global biopharmaceutical company committed to transforming the lives of patients living with severe diseases, is proud to announce the launch of FASTRAX Canada, a ground-breaking initiative ...

UCB Canada Inc. is pleased to announce that PrRYSTIGGO® (rozanolixizumab injection) has received authorization from Health Canada for the treatment of adult patients with generalized myasthenia ...

OAKVILLE, ON, Sept. 26, 2018 /CNW/ - UCB Canada Inc. announced today that CIMZIA® (certolizumab pegol) solution for injection in a single-use pre-filled Autoinjector is now available through ...

UCB, a global biopharmaceutical company committed to transforming the lives of patients living with severe diseases, is proud to announce the launch of FASTRAX Canada, a ground-breaking initiative ...

UCB Canada Inc. is pleased to announce that PrRYSTIGGO® (rozanolixizumab injection) has received authorization from Health Canada for the treatment of adult patients with generalized myasthenia gravis ...

UCB and University Health Network (UHN) Collaborate to Enhance Axial Spondyloarthritis (axSpA) Care in Canada Français News provided by UCB Canada Inc. Aug 01, 2024, 09:00 ET ...